The UK is witnessing a significant surge in interest surrounding mind-altering substances. Beyond the familiar use of psilocybin and LSD, investigators and explorers are increasingly exploring less-charted areas, particularly copyright and the nascent cannabinoid, CBG compound. The evolving movement encompasses clinical trials into psychological we